Study on Cervical Cancer Genetic and Molecular Features

Research Overview

In a 2017 study, researchers explored the connections between genetic, molecular, and histological characteristics of cervical cancers. The aim was to identify clinically relevant aspects that could enhance diagnosis, prognosis, and treatment. The study uncovered various genetic, RNA-related, protein-related, and histological features pertinent to cervical cancer, influenced by HPV strain, mutations in specific cellular pathways, DNA regulation, and cell type.

Understanding Cancer Mutations

Cancer cells develop through the accumulation of mutations, which entail changes in DNA base pair sequences, gene copy numbers, or chromosome structures. These mutations subsequently alter the shape and composition of RNA and proteins, impacting cellular functions and their regulation based on DNA blueprints. Identifying these mutations and characterizing their effects can yield valuable information for clinical applications.

Cervical Cancer Prevalence and HPV Strains

Cervical cancer ranks as the fourth most common cancer among women globally, primarily attributed to HPV strains that trigger tumor formation. The risk of cervical cancer varies significantly depending on the specific HPV strains a woman carries and the characteristics of the cancerous cells present in the cervix. However, the mechanisms underlying these HPV-related traits remain inadequately understood, highlighting the need for clinically relevant classifications for cervical cancer patients.

Insights from the 2017 Nature Paper

The 2017 study published in Nature involved an analysis of DNA, RNA, and proteins from 228 cases of invasive cervical cancer. The researchers aimed to find links between genetic and molecular alterations and clinical indicators of various cervical cancer forms. Tumor samples were collected from women who had not previously received radiation therapy or chemotherapy.

Analysis of Tumor Characteristics

The researchers examined tumors to detect abnormal DNA sequences, gene copy numbers, DNA methylation patterns, mRNA levels (reflecting protein production), and protein composition, including genes integrated by HPV. They identified five genes—SHKBP1, ERBB3, CASP8, HLA-A, and TGFBR2—as significantly mutated and newly linked to cervical cancer.

Additional Mutations and Gene Implications

Nine other genes—PIK3CA, EP300, FBXW9, HLA-B, PTEN, NFE2L2, ARID1A, KRAS, and MAPK1—were also found to be significantly mutated, consistent with prior research. Mutations in HLA-A, HLA-B, NFE2L2, MAPK1, CASP8, SHKBP1, and TGFBR2 were specifically associated with squamous carcinomas, while other mutations were observed in both squamous and adenocarcinomas.

Gene Multiplications and Deletions

The study identified new gene amplifications linked to cervical cancer, including those in EGFR, CD274, PDCD1LG2, KLF5, and BCAR4. CD274 and PDCD1LG2 are involved in immune responses, while BCAR4 is associated with enhanced metastasis in estrogen-resistant breast cancer. Whole-genome analysis revealed duplications within the BCAR4 gene and multiplications on chromosome 16. Newly implicated deletions included TGFBR2 and SMAD4.

RNA-Related Gene Groupings

Three mRNA-related gene groups emerged, associated with KRAS, ERBB3, and HLA-A. These included:

– A keratin-high group common to squamous tumors, producing high mRNA levels for keratin, lacking KRAS mutations.
– A keratin-low group, also common to squamous tumors, producing low keratin mRNA levels, associated with A7-type HPV.
– An adenocarcinoma group linked to A7-type HPV, characterized by high DNA methylation levels.

Endometrial-Like Cervical Tumors

Among the 178 cervical cancer samples, eight displayed characteristics resembling endometrial cancers, with five classified as adenocarcinomas. Notably, seven of these cases tested negative for HPV. These tumors accounted for significant percentages of ARID1A, KRAS, and PTEN mutations in the study.

Conclusions and Future Implications

The findings highlight a range of genetic and molecular traits that may assist in characterizing cervical cancer based on HPV strain and mutations. A notable 70% of samples exhibited mutations related to the PI3K/MAPK and TGFβ signaling pathways, suggesting that these pathways, along with genes like PI3K/Akt, TGFBR2, and PTEN, could serve as potential therapeutic targets. Existing therapies targeting newly implicated genes BCAR4 and ERBB3, alongside PTEN and ARID1A, may warrant further investigation for their effectiveness in treating cervical cancers.

Written By: Raishard Haynes, MBS